Several analysts have recently updated their ratings and price targets for Allergan PLC. (NYSE: AGN):

  • 7/17/2017 – Allergan PLC. had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $273.00 price target on the stock, up previously from $265.00.
  • 7/16/2017 – Allergan PLC. was given a new $284.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 7/14/2017 – Allergan PLC. had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $231.00 price target on the stock.
  • 7/11/2017 – Allergan PLC. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $270.00 price target on the stock. According to Zacks, “Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 6/26/2017 – Allergan PLC. was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $242.88 price target on the stock.
  • 6/24/2017 – Allergan PLC. was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/19/2017 – Allergan PLC. was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $234.38 price target on the stock.
  • 6/17/2017 – Allergan PLC. was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/16/2017 – Allergan PLC. is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $231.00 price target on the stock.
  • 6/12/2017 – Allergan PLC. was given a new $284.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 6/9/2017 – Allergan PLC. had its price target lowered by analysts at Mizuho from $275.00 to $267.00. They now have a “buy” rating on the stock.
  • 6/8/2017 – Allergan PLC. was given a new $400.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 6/2/2017 – Allergan PLC. was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 5/25/2017 – Allergan PLC. had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein.

Shares of Allergan PLC. (AGN) opened at 247.53 on Tuesday. The company has a market capitalization of $83.14 billion, a P/E ratio of 7.71 and a beta of 1.16. The firm has a 50-day moving average price of $231.35 and a 200 day moving average price of $230.10. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $261.27.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.03. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business had revenue of $3.57 billion for the quarter, compared to the consensus estimate of $3.53 billion. During the same period last year, the business posted $3.04 EPS. The business’s revenue was up 5.1% compared to the same quarter last year. On average, equities research analysts predict that Allergan PLC. will post $16.09 earnings per share for the current year.

In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.36% of the company’s stock.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.